What's Happening?
Osita Chidoka, a former Aviation Minister and Chancellor of the Athena Centre for Policy and Leadership, has called on Nigerian pharmaceutical manufacturers to elevate their production standards to meet
global benchmarks. Speaking at the 29th national conference of the Association of Industrial Pharmacists of Nigeria in Ilorin, Chidoka emphasized the need for the industry to move beyond basic compliance with local regulations and align with international standards set by the World Health Organisation (WHO) and the United States Food and Drug Administration (FDA). He highlighted the heavy reliance on imported Active Pharmaceutical Ingredients (APIs), which constitutes 70-80% of the industry's needs, as a significant weakness. Chidoka pointed out that this dependency, coupled with rising medicine costs, poses a threat to affordable healthcare and economic resilience in Nigeria.
Why It's Important?
Chidoka's call for higher standards in pharmaceutical manufacturing is crucial for Nigeria's health security and economic competitiveness. By adopting international standards, Nigerian manufacturers could improve product quality and gain access to broader markets under frameworks like the African Continental Free Trade Area. This shift could reduce the country's dependency on imported APIs, potentially lowering the cost of medicines and making healthcare more affordable for Nigerians. The move could also enhance the industry's global competitiveness, allowing it to tap into international markets and contribute to national economic growth. The emphasis on quality and innovation could lead to a more resilient pharmaceutical sector, capable of withstanding economic and regulatory challenges.
What's Next?
Pharmaceutical manufacturers in Nigeria are expected to respond to Chidoka's call by reassessing their compliance strategies and operational practices. This may involve investing in new technologies and processes to meet WHO and FDA standards. Industry leaders and policymakers might also engage in discussions to address the structural challenges identified, such as the reliance on imported APIs. The conference's outcomes could lead to policy recommendations aimed at strengthening the local pharmaceutical industry. Stakeholders, including government representatives and industry experts, may collaborate to develop a roadmap for achieving these international standards, potentially influencing future regulatory frameworks and industry practices.
